Nasdaq:GILD
GILEAD SCIENCES, INC.
A premier biopharmaceutical innovator delivering breakthrough therapies for chronic viral infections and oncology across the United States and international markets.
Key Metrics
Investment Thesis
Bull Case
Gilead offers an attractive investment opportunity due to its diversified revenue streams reducing reliance on any single product, a history of consistent dividend payments supported by robust free cash flow, and the potential for significant value creation through strategic acquisitions in high-growth therapeutic areas.
Bear Case
The stock carries valuation risk given the substantial long-term debt load of $22.13B and recent volatility in net income, while heavy R&D spending and the inherent unpredictability of drug development timelines could impact future profitability if key clinical milestones are not met.
About GILEAD SCIENCES, INC.
Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in the research, development, and commercialization of innovative medicines primarily for HIV/AIDS, oncology, liver disease, and rare diseases. The company serves global markets with a diverse portfolio including branded small molecules and biosimilars, leveraging its strong R&D capabilities to address unmet medical needs.
Analysis
Management Discussion
Recent financial performance reflects strong operational efficiency with operating cash flow reaching $10.02B despite significant investments in acquisitions totaling $1.07B and capital expenditures of $563M. The company successfully navigated revenue growth to $29.44B while managing a substantial decline in cash reserves from $9.99B to $7.56B due to net cash outflows from financing and investing activities.
Industry Overview
The global biopharmaceutical industry is characterized by intense competition for novel mechanisms of action, high regulatory barriers to entry, and a shift towards value-based pricing models. Gilead operates in a mature yet innovative sector where success depends on continuous pipeline development and the ability to navigate complex healthcare reimbursement environments.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $27.28B | $27.12B | $28.75B | $29.44B |
| Cost of Revenue | $5.66B | $6.50B | $6.25B | $6.23B |
| Gross Profit | $21.62B | $20.62B | $22.50B | $23.21B |
| Operating Expenses | $14.29B | $13.01B | $20.84B | $13.19B |
| Operating Income | $7.33B | $7.61B | $1.66B | $10.02B |
| G&A | $5.67B | $6.09B | $6.09B | $5.77B |
| Stock-Based Comp | $637.0M | $766.0M | $835.0M | $894.0M |
| Depreciation | $323.0M | $354.0M | $381.0M | $370.0M |
| Amortization | $1.80B | $2.30B | $2.40B | $2.40B |
| Other OpEx | $8.62B | $6.92B | $14.75B | $7.41B |
| Non-Operating Income | $-1.52B | $-746.0M | $-972.0M | $-226.0M |
| Interest Expense | $935.0M | $944.0M | — | — |
| Pre-Tax Income | $5.81B | $6.86B | $690.0M | $9.80B |
| Income Tax | $1.25B | $1.25B | $211.0M | $1.29B |
| Continuing Ops | $4.57B | $5.61B | $479.0M | $8.51B |
| Discontinued Ops | $0 | $1.0M | $1.0M | $0 |
| Net Income | $4.57B | $5.61B | $480.0M | $8.51B |
| Minority Interest | $-26.0M | $-52.0M | $0 | $0 |
| Net to Common | $4.59B | $5.67B | $480.0M | $8.51B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $14.44B | $16.09B | $19.17B | $18.34B |
| Cash & Equivalents | $5.41B | — | — | — |
| Marketable Securities | $973.0M | $1.18B | $0 | $68.0M |
| Accounts Receivable | $4.78B | $4.66B | $4.42B | $4.91B |
| Inventory | $1.51B | $1.79B | $1.71B | $1.77B |
| Prepaid Expenses | $1.77B | $2.37B | $3.05B | $4.02B |
| Other Current Assets | $0 | $6.08B | $9.99B | $7.56B |
| Long-Term Assets | $48.73B | $46.04B | $39.82B | $40.68B |
| PP&E (Net) | $5.47B | $5.32B | $5.41B | $5.61B |
| Intangibles | $28.89B | $26.45B | $19.95B | $16.98B |
| Goodwill | $8.31B | $8.31B | $8.31B | $8.31B |
| Operating Leases | $505.0M | $581.0M | $515.0M | $532.0M |
| LT Securities | $1.25B | $1.16B | $0 | $2.97B |
| Other LT Assets | $4.29B | $4.21B | $5.63B | $6.28B |
| Total Assets | $63.17B | $62.12B | $58.99B | $59.02B |
| Current Liabilities | $11.24B | $11.28B | $12.00B | $11.81B |
| Accounts Payable | $905.0M | $550.0M | $833.0M | $715.0M |
| Current Debt | $2.27B | $1.80B | $1.81B | $2.81B |
| Current Leases | $111.0M | $125.0M | $113.0M | $102.0M |
| Taxes Payable | $959.0M | $1.21B | $1.65B | $92.0M |
| Other Current Liab | $6.99B | $7.60B | $7.60B | $8.10B |
| Long-Term Liabilities | $30.73B | $28.10B | $27.75B | $24.59B |
| Long-Term Debt | $22.96B | $23.19B | $24.90B | $22.13B |
| LT Operating Leases | $467.0M | $546.0M | $498.0M | $503.0M |
| Other LT Liab | $3.38B | $2.32B | $1.52B | $1.06B |
| Total Liabilities | $41.96B | $39.38B | $39.75B | $36.41B |
| Shareholders' Equity | $21.21B | $22.75B | $19.25B | $22.62B |
| Paid-In Capital | $5.55B | $6.50B | $7.70B | $8.93B |
| Retained Earnings | $15.69B | $16.30B | $11.50B | $13.73B |
| AOCI | $2.0M | $28.0M | $132.0M | $39.0M |
| Total L&E | $63.17B | $62.12B | $58.99B | $59.02B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $4.57B | $5.61B | $480.0M | $8.51B |
| Non-Cash Adjustments | $5.63B | $3.57B | $10.41B | $1.58B |
| Working Capital Changes | $-1.13B | $-1.18B | $-62.0M | $-69.0M |
| Cash from Operations | $9.07B | $8.01B | $10.83B | $10.02B |
| Capital Expenditures | $728.0M | $585.0M | $523.0M | $563.0M |
| Cash from Investing | $-2.47B | $-2.27B | $-3.45B | $-4.79B |
| Share Buybacks | $1.40B | $1.00B | $1.15B | $1.92B |
| Dividends Paid | $3.71B | $3.81B | $3.92B | $4.00B |
| Cash from Financing | $-6.47B | $-5.12B | $-3.43B | $-7.75B |
| FX Effect | $-63.0M | $57.0M | $-40.0M | $92.0M |
| Net Change in Cash | $74.0M | $673.0M | $3.91B | $-2.43B |
| Beginning Cash | $5.34B | $5.41B | $6.08B | $9.99B |
| Ending Cash | $5.41B | $6.08B | $9.99B | $7.56B |
Frequently Asked Questions
How does GILEAD SCIENCES, INC. make money?
The company's revenue is driven by its core HIV franchise which provides steady cash flow, a growing biosimilar portfolio in oncology and immunology, specialized treatments for liver diseases including hepatitis C, and an expanding pipeline in autoimmune disorders and rare genetic conditions.
What are the main risks for GILD?
Investors should consider the risk of patent expirations eroding revenue from key products, potential delays or failures in clinical trials for new drug candidates, regulatory hurdles such as pricing negotiations with government payers, and the impact of global healthcare policy changes on reimbursement rates.
What is GILD's competitive advantage?
Gilead maintains a robust competitive moat through an extensive patent fortress protecting its blockbuster drugs, a highly efficient commercialization team with global reach, and significant cash reserves enabling strategic M&A and sustained R&D investment without reliance on external financing.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.